We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Nuvalent Inc (NUVL) USD0.0001 A

Sell:$67.87 Buy:$68.01 Change: $1.27 (1.90%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Change: $1.27 (1.90%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Change: $1.27 (1.90%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.

Contact details

One Broadway, 14th Floor
United States
+1 (857) 3577000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$4.39 billion
Shares in issue:
64.56 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • James Porter
    President, Chief Executive Officer, Director
  • Alexandra Balcom
    Chief Financial Officer, Treasurer
  • Henry Pelish
    Senior Vice President - Drug Development
  • John Soglia
    Senior Vice President - Translational Development
  • Darlene Noci
    Chief Development Officer
  • Christopher Turner
    Chief Medical Officer
  • Deborah Miller
    Chief Legal Officer, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.